[Asia Economy Reporter Seongpil Cho] Celltrion announced on the 28th that it has signed a supply contract for biosimilar antibody drugs (Remsima IV, Herzuma, Remsima SC) with Celltrion Healthcare.
The contract amount is 252.3925 billion KRW, which corresponds to 22.36% of the sales in 2019.
The contract period is until the 30th of this month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
